DK3419624T3 - Fremgangsmåder til anvendelse af fxr-agonister - Google Patents
Fremgangsmåder til anvendelse af fxr-agonister Download PDFInfo
- Publication number
- DK3419624T3 DK3419624T3 DK17708341.7T DK17708341T DK3419624T3 DK 3419624 T3 DK3419624 T3 DK 3419624T3 DK 17708341 T DK17708341 T DK 17708341T DK 3419624 T3 DK3419624 T3 DK 3419624T3
- Authority
- DK
- Denmark
- Prior art keywords
- procedures
- fxr agonists
- fxr
- agonists
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662298113P | 2016-02-22 | 2016-02-22 | |
| PCT/IB2017/050962 WO2017145040A1 (en) | 2016-02-22 | 2017-02-20 | Methods for using fxr agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3419624T3 true DK3419624T3 (da) | 2021-04-19 |
Family
ID=58192341
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK17708341.7T DK3419624T3 (da) | 2016-02-22 | 2017-02-20 | Fremgangsmåder til anvendelse af fxr-agonister |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US11110083B2 (da) |
| EP (2) | EP3842043A1 (da) |
| JP (1) | JP6941109B2 (da) |
| KR (1) | KR20180115700A (da) |
| CN (1) | CN108697703A (da) |
| AU (1) | AU2017223154B2 (da) |
| CA (1) | CA3014733A1 (da) |
| DK (1) | DK3419624T3 (da) |
| ES (1) | ES2862194T3 (da) |
| HK (1) | HK1257649A1 (da) |
| HU (1) | HUE053743T2 (da) |
| IL (1) | IL261036A (da) |
| PL (1) | PL3419624T3 (da) |
| PT (1) | PT3419624T (da) |
| RU (1) | RU2737324C2 (da) |
| SI (1) | SI3419624T1 (da) |
| TW (1) | TW201733583A (da) |
| WO (1) | WO2017145040A1 (da) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108697702A (zh) * | 2016-02-22 | 2018-10-23 | 诺华股份有限公司 | 使用fxr激动剂的方法 |
| CN108697704A (zh) | 2016-02-22 | 2018-10-23 | 诺华股份有限公司 | 使用fxr激动剂的方法 |
| JOP20190040A1 (ar) * | 2016-09-14 | 2019-03-10 | Novartis Ag | توليفة من ناهضات fxr |
| JP2019530696A (ja) * | 2016-10-05 | 2019-10-24 | ノバルティス アーゲー | 線維性、硬変性の疾患もしくは障害を治療または予防するためのｆｘｒアゴニストを含む組合せ組成物 |
| CN108017636A (zh) * | 2016-11-04 | 2018-05-11 | 合帕吉恩治疗公司 | 作为fxr调节剂的含氮杂环化合物 |
| AR114930A1 (es) | 2017-09-12 | 2020-11-11 | Novartis Ag | Composición farmacéutica |
| JP2020533339A (ja) * | 2017-09-13 | 2020-11-19 | ノバルティス アーゲー | Ｆｘｒアゴニストを含む組合せ |
| US10730863B2 (en) | 2017-11-01 | 2020-08-04 | Bristol-Myers Squibb Company | Bridged bicyclic compounds as farnesoid X receptor modulators |
| KR20200081435A (ko) | 2017-11-01 | 2020-07-07 | 브리스톨-마이어스 스큅 컴퍼니 | 파르네소이드 x 수용체 조정제로서의 멀티시클릭 화합물 |
| KR20200083528A (ko) | 2017-11-01 | 2020-07-08 | 브리스톨-마이어스 스큅 컴퍼니 | 파르네소이드 x 수용체 조정제로서의 스피로시클릭 화합물 |
| WO2019089670A1 (en) | 2017-11-01 | 2019-05-09 | Bristol-Myers Squibb Company | Alkene compounds as farnesoid x receptor modulators |
| EP3704112B1 (en) | 2017-11-01 | 2023-09-27 | Bristol-Myers Squibb Company | Alkene spirocyclic compounds as farnesoid x receptor modulators |
| WO2019106550A1 (en) * | 2017-11-30 | 2019-06-06 | Novartis Ag | Fxr agonists for the treatment of liver diseases |
| EP3730491B1 (en) | 2017-12-22 | 2022-07-20 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Isoxazole derivative, preparation method therefor, and use thereof |
| WO2020061114A1 (en) * | 2018-09-18 | 2020-03-26 | Metacrine, Inc. | Farnesoid x receptor agonists for the treatment of disease |
| AR118050A1 (es) | 2019-02-15 | 2021-09-15 | Bristol Myers Squibb Co | Compuestos bicíclicos sustituidos como moduladores del receptor farnesoide x |
| CN114025760B (zh) * | 2019-07-18 | 2023-12-01 | 埃尼奥制药公司 | 改进的用eyp001的治疗 |
| US20220241376A1 (en) | 2019-07-18 | 2022-08-04 | Enyo Pharma | Method for decreasing adverse-effects of interferon |
| US20220331341A1 (en) * | 2019-09-30 | 2022-10-20 | Novartis Ag | Treatment comprising the use of fxr agonists |
| CN114945361A (zh) | 2020-01-15 | 2022-08-26 | 法国国家卫生及研究医学协会 | Fxr激动剂在治疗丁型肝炎病毒感染中的用途 |
| EP4277622A1 (en) | 2021-01-14 | 2023-11-22 | ENYO Pharma | Synergistic effect of a fxr agonist and ifn for the treatment of hbv infection |
| CN114903905B (zh) * | 2021-02-09 | 2024-04-02 | 中国人民解放军陆军军医大学第二附属医院 | 甘氨脱氧胆酸在制备治疗肝内胆汁淤积药物中的应用及其药物组合物 |
| WO2022229302A1 (en) | 2021-04-28 | 2022-11-03 | Enyo Pharma | Strong potentiation of tlr3 agonists effects using fxr agonists as a combined treatment |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7319109B2 (en) * | 2002-11-22 | 2008-01-15 | Smith Kline Beecham Corporation | Farnesoid X receptor agonists |
| CU24152B1 (es) * | 2010-12-20 | 2016-02-29 | Irm Llc | 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr |
| CN108697704A (zh) | 2016-02-22 | 2018-10-23 | 诺华股份有限公司 | 使用fxr激动剂的方法 |
| CN108697702A (zh) | 2016-02-22 | 2018-10-23 | 诺华股份有限公司 | 使用fxr激动剂的方法 |
-
2017
- 2017-02-20 US US16/078,431 patent/US11110083B2/en active Active
- 2017-02-20 JP JP2018544147A patent/JP6941109B2/ja active Active
- 2017-02-20 PL PL17708341T patent/PL3419624T3/pl unknown
- 2017-02-20 EP EP21150907.0A patent/EP3842043A1/en not_active Withdrawn
- 2017-02-20 DK DK17708341.7T patent/DK3419624T3/da active
- 2017-02-20 ES ES17708341T patent/ES2862194T3/es active Active
- 2017-02-20 SI SI201730697T patent/SI3419624T1/sl unknown
- 2017-02-20 CA CA3014733A patent/CA3014733A1/en not_active Abandoned
- 2017-02-20 AU AU2017223154A patent/AU2017223154B2/en not_active Ceased
- 2017-02-20 KR KR1020187023975A patent/KR20180115700A/ko unknown
- 2017-02-20 PT PT177083417T patent/PT3419624T/pt unknown
- 2017-02-20 EP EP17708341.7A patent/EP3419624B1/en active Active
- 2017-02-20 WO PCT/IB2017/050962 patent/WO2017145040A1/en active Application Filing
- 2017-02-20 RU RU2018133158A patent/RU2737324C2/ru active
- 2017-02-20 HU HUE17708341A patent/HUE053743T2/hu unknown
- 2017-02-20 CN CN201780012782.2A patent/CN108697703A/zh active Pending
- 2017-02-22 TW TW106105852A patent/TW201733583A/zh unknown
-
2018
- 2018-08-07 IL IL261036A patent/IL261036A/en unknown
-
2019
- 2019-01-02 HK HK19100007.0A patent/HK1257649A1/zh unknown
-
2021
- 2021-07-23 US US17/383,634 patent/US20210386729A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| RU2018133158A (ru) | 2020-03-24 |
| CN108697703A (zh) | 2018-10-23 |
| JP6941109B2 (ja) | 2021-09-29 |
| EP3419624B1 (en) | 2021-01-13 |
| RU2737324C2 (ru) | 2020-11-27 |
| IL261036A (en) | 2018-10-31 |
| US11110083B2 (en) | 2021-09-07 |
| EP3842043A1 (en) | 2021-06-30 |
| PT3419624T (pt) | 2021-04-07 |
| ES2862194T3 (es) | 2021-10-07 |
| JP2019511476A (ja) | 2019-04-25 |
| WO2017145040A1 (en) | 2017-08-31 |
| HK1257649A1 (zh) | 2019-10-25 |
| SI3419624T1 (sl) | 2021-05-31 |
| TW201733583A (zh) | 2017-10-01 |
| HUE053743T2 (hu) | 2021-07-28 |
| PL3419624T3 (pl) | 2021-08-02 |
| EP3419624A1 (en) | 2019-01-02 |
| AU2017223154B2 (en) | 2019-08-15 |
| CA3014733A1 (en) | 2017-08-31 |
| RU2018133158A3 (da) | 2020-06-08 |
| US20210386729A1 (en) | 2021-12-16 |
| AU2017223154A1 (en) | 2018-08-30 |
| KR20180115700A (ko) | 2018-10-23 |
| US20190083481A1 (en) | 2019-03-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3419625T3 (da) | Fremgangsmåder til anvendelse af fxr-agonister | |
| DK3419624T3 (da) | Fremgangsmåder til anvendelse af fxr-agonister | |
| DK3368060T3 (da) | Glugacon-receptor-agonister | |
| DK3286311T3 (da) | Fremgangsmåde til behandling af maligniteter | |
| DK3294700T3 (da) | Fremgangsmåde til fremstilling af limonen-4-ol | |
| DK3072835T3 (da) | Fremgangsmåde til fremføring | |
| DK3466432T3 (da) | Fremgangsmåder til behandling af pulmonale non-tuberkuløse mykobakterielle infektioner | |
| DK3628732T3 (da) | Transposasesammensætninger til reduktion af insertionsbias | |
| HK1257648A1 (zh) | Fxr促效劑之使用方法 | |
| DK3229995T3 (da) | Fremgangsmåde for fremstilling af et endestykke | |
| DK3512857T3 (da) | Spiro-bicykliske inhibitorer af menin-mll-interaktion | |
| DK3529233T3 (da) | Fremgangsmåde til fremstilling af 3-alkylsulfanyl-2-chlor-n-(1-alkyl-1h-tetrazol-5-yl)-4-trifluoromethyl-benzamider | |
| DK3366832T3 (da) | Indretning til identifikation af stoftype | |
| DK3529262T3 (da) | Fremgangsmåder til fremme af t-cellerespons | |
| DK3117259T3 (da) | Vurdering af farvningskvalitet | |
| DK3113675T3 (da) | Fremgangsmåde til overførsel af point-of-care-testdata | |
| DK3166855T3 (da) | Fremgangsmåde for tilvejebringelse af foldelinjer | |
| DK3274143T3 (da) | Fremgangsmåde til fremstilling af lignocellulosematerialer | |
| DK3120153T3 (da) | Cellulær-baseret fremgangsmåde til bestemmelse af muligheden for defibrotid | |
| DK3507282T3 (da) | Fremgangsmåde til fremstilling af indolcarboxamidforbindelser | |
| DK3430072T3 (da) | Fremgangsmåde til oprensning af poloxamerer | |
| DK3265564T3 (da) | Fremgangsmåde til modulering af mecp2-ekspression | |
| DK3163041T3 (da) | Indretning til rensning af udstødning | |
| DK3148993T3 (da) | Fremgangsmåde til fremstilling af thiazolderivater | |
| DK3161136T3 (da) | Fremgangsmåde til berigelse af mikrovesikler |